

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/249,543	02/12/99	EVANS	NEB-154

GREGORY D WILLIAMS  
GENERAL COUNSEL  
NEW ENGLAND BIOLABS INC  
32 TOZER ROAD  
BEVERLY MA 01915

HM12/0831



EXAMINER
MOORE, W

ART UNIT	PAPER NUMBER
1652	

DATE MAILED: 08/31/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

**ACTION:**

sequence  
NEW ENGLAND BIOLABS, INC.  
32 Tozer Rd. Beverly, MA 01915

Date Rec'd

Docketed For

By



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: C MMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------



EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

3

DATE MAILED:

Commissioner of Patents


Please find below a communication from the EXAMINER in charge of this application.


This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report. Specifically, problems with designations required by the new rules are indicated in Item 10 of the attached Error Summary.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to William W. Moore whose telephone number is (703) 308-0583. The examiner can be reached Monday through Friday from 9:00 AM to 5:30PM EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703) 308-3804. Papers related to this application may be submitted to Group 1800 by facsimile transmission. The faxing of such papers must conform with the notice published November 15, 1989 in the Official Gazette, 1096 OG 30. Informal and unofficial communications may be sent to the Art Unit 1652 FAX number, (703) 308-0294. Official filings should be sent to the Technical Center 1600 FAX number which is (703) 308-4556.

William W. Moore  
August 27, 1999

  
PONNATHAPU ACHUTAMURTHY  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600



Application No. 09/249,543

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821( ).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☒ 7. Other: See attached Error Report and Error Summary

**Applicant must provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**Please return a copy of this notice with your response.**

# Raw Sequence Listing Error Summary

## ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER:


09/249543

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1      **Wrapped Nucleics**      The number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2      **Wrapped Aminos**      The amino acid number/text at the end of each line "wrapped" down to the next line.  
This may occur if your file was retrieved in a word processor after creating it.  
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3      **Incorrect Line Length**      The rules require that a line not exceed 72 characters in length. This includes spaces.  
All text must be visible on page.
- 4      **Misaligned Amino Acid Numbering**      The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and uses spacing between the numbers.
- 5      **Non-ASCII**      This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.  
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6      **Variable Length**      Sequence(s)      contain n's or Xaa's which represented more than one residue.  
As per the rules, each n or Xaa can only represent a single residue.  
Please present the maximum number of each residue having variable length and indicate in the (ix) features section that some may be missing.
- 7      **Wrong Designation**      Sequence(s)      contain amino acid or nucleic acid designators which are not standard representations as per the Sequence Rules (Please refer to paragraph 1.822)
- 8      **Skipped Sequences (OLD RULES)**      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence:  
(2) INFORMATION FOR SEQ ID NO:X:  
(1) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")  
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:  
This sequence is intentionally skipped  
  
Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9      **Skipped Sequences (NEW RULES)**      Sequence(s)      missing. If intentional, please use the following format for each skipped sequence.  
<210> sequence id number  
<400> sequence id number  
000
- 10      **Use of N's or Xaa's (NEW RULES)**      Use of N's and/or Xaa's have been detected in the Sequence Listing.  
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
- 11      **Use of <213>Organism (NEW RULES)**      Sequence(s)      are missing this mandatory field or its response.
- 12      **Use of <220>Feature (NEW RULES)**      Sequence(s)      are missing the <220>Feature and associated headings.  
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"  
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32)  
(Sec. 1.823 of new Sequence Rules)
- 13      **Wrong Format**      File submitted was in the alphabetical heading format of the Old Sequence Rules. This is invalid since the "Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures" Federal Register Notice, Vol. 63, No. 104, June 1, 1998, p. 29620 applies to applications filed on or after July 1, 1998.  
AKS-Biotechnology Systems Branch- 7/10/98



PAGE: 1



OIPE

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/249,543

DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW  
Does Not Comply  
Corrected Diskette Needed

This Raw Listing contains the General Information  
Section and up to first 5 pages.

1 <110> APPLICANT: Evans, Thomas  
2 Xu, Ming-Qun  
3 <120> TITLE OF INVENTION: Intein-Mediated Protein Ligation Of Expressed Proteins  
4 <130> FILE REFERENCE: NEB-154  
5 <140> CURRENT APPLICATION NUMBER: US/09/249,543  
6 <141> CURRENT FILING DATE: 1999-02-12  
7 <160> NUMBER OF SEQ ID NOS: 24  
8 <170> SOFTWARE: PatentIn Ver. 2.0  
9 <210> SEQ ID NO 1  
10 <211> LENGTH: 99  
11 <212> TYPE: DNA  
12 <213> ORGANISM: Artificial Sequence  
13 <220> FEATURE:  
14 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
15 Synthesized From Methanobacterium  
16 thermoautotrophicum.  
17 <400> SEQUENCE: 1  
18 tcgaggcaac caaccctgc gtatccggtg acaccattgt aatgactagt ggcgggtccgc 60  
19 gcactgtggc tgaactggag ggcaaaccgt tcaccgcac 99  
20 <210> SEQ ID NO 2  
21 <211> LENGTH: 93  
22 <212> TYPE: DNA  
23 <213> ORGANISM: Artificial Sequence  
24 <220> FEATURE:  
25 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
26 Synthesized From Methanobacterium  
27 thermoautotrophicum.  
28 <400> SEQUENCE: 2  
29 ccggttggt gctcgccaca gttgtgtaca atgaagccat tagcagtga tgcgctagca 60  
30 ccgtaaacag tagcgtcata aacatcctgg cgg 93  
31 <210> SEQ ID NO 3  
32 <211> LENGTH: 100  
33 <212> TYPE: DNA  
34 <213> ORGANISM: Artificial Sequence  
35 <220> FEATURE:  
36 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
37 Synthesized From Methanobacterium  
38 thermoautotrophicum.  
39 <400> SEQUENCE: 3  
40 tgattcgcg ctctggctac ccatgccct caggtttctt ccgcacctgt gaacgtgacg 60  
41 tatatgatct gcgtacacgt gagggtcatt gcttacgttt 100  
42 <210> SEQ ID NO 4  
43 <211> LENGTH: 100  
44 <212> TYPE: DNA

PAGE: 2

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/249,543DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW

45 <213> ORGANISM: Artificial Sequence  
46 <220> FEATURE:  
47 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
48 Synthesized From Methanobacterium  
49 thermoautotrophicum.  
50 <400> SEQUENCE: 4  
51 gacccatgat caccgtgttc tggatgatgga tggatggcctg gaatggcgtg ccgcgggtga 60  
52 actggaacgc ggcgaccgcc tggatgatgga tgatgcagct  
53 <210> SEQ ID NO 5  
54 <211> LENGTH: 87  
55 <212> TYPE: DNA  
56 <213> ORGANISM: Artificial Sequence  
57 <220> FEATURE:  
58 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
59 Synthesized From Methanobacterium  
60 thermoautotrophicum.  
61 <400> SEQUENCE: 5  
62 ggcgagtttc cggcactggc aaccttccgt ggcctgcgtg gcgctggccg ccaggatgtt 60  
63 tatgacgcta ctgtttacgg tgctagc 87  
64 <210> SEQ ID NO 6  
65 <211> LENGTH: 49  
66 <212> TYPE: DNA  
67 <213> ORGANISM: Artificial Sequence  
68 <220> FEATURE:  
69 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
70 Synthesized From Methanobacterium  
71 thermoautotrophicum.  
72 <400> SEQUENCE: 6  
73 gcattcactg ctaatggctt cattgtacac aactgtggcg agcagccaa 49  
74 <210> SEQ ID NO 7  
75 <211> LENGTH: 100  
76 <212> TYPE: DNA  
77 <213> ORGANISM: Artificial Sequence  
78 <220> FEATURE:  
79 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
80 Synthesized From Methanobacterium  
81 thermoautotrophicum.  
82 <400> SEQUENCE: 7  
83 ccagcgccac gcaggccacg gaagggttgc agtgccggaa actcgccagc tgcattcatcc 60  
84 atcaccaggc ggtcgccgcg ttccagttca cccgcggcac 100  
85 <210> SEQ ID NO 8  
86 <211> LENGTH: 90  
87 <212> TYPE: DNA  
88 <213> ORGANISM: Artificial Sequence  
89 <220> FEATURE:  
90 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
91 Synthesized From Methanobacterium  
92 thermoautotrophicum.  
93 <400> SEQUENCE: 8  
94 gccattccag gccaccatcc atcaccagaa cacggtgatc atgggtcaaa cgtaagcaat 60



PAGE: 3

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/249,543

DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW

```

95      gaccctcacg tgtacgcaga tcatatacgt                      90
96  <210> SEQ ID NO 9
97  <211> LENGTH: 97
98  <212> TYPE: DNA
99  <213> ORGANISM: Artificial Sequence
100 <220> FEATURE:
101 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically
102      Synthesized From Methanobacterium
103      thermoautotrophicum.
104 <400> SEQUENCE: 9
105      cacgttcaca ggtgcggaag aaacctgagg ggcattgggta gccagagccg cgaatcagtg 60
106      cggatgaacgg ttgcccctcc agttcagcca cagtgcg                      97
107 <210> SEQ ID NO 10
108 <211> LENGTH: 55
109 <212> TYPE: DNA
110 <213> ORGANISM: Artificial Sequence
111 <220> FEATURE:
112 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically
113      Synthesized From Methanobacterium
114      thermoautotrophicum.
115 <400> SEQUENCE: 10
116      cggaccgcga ctagtcatta caatggtgtc accggatacg caggggttgg ttgcc      55
117 <210> SEQ ID NO 11
118 <211> LENGTH: 45
119 <212> TYPE: DNA
120 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically
123      Synthesized From Methanobacterium
124      thermoautotrophicum.
125 <400> SEQUENCE: 11
126      tcgaggcaac caacgcatgc gtatccggtg acaccattgt aatga              45
127 <210> SEQ ID NO 12
128 <211> LENGTH: 45
129 <212> TYPE: DNA
130 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically
133      Synthesized From Methanobacterium
134      thermoautotrophicum.
135 <400> SEQUENCE: 12
136      ctagtcatta caatggtgtc accggatacg catgcgttgg ttgcc              45
137 <210> SEQ ID NO 13
138 <211> LENGTH: 36
139 <212> TYPE: DNA
140 <213> ORGANISM: Artificial Sequence
141 <220> FEATURE:
142 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically
143      Synthesized From Methanobacterium
144      thermoautotrophicum.

```

PAGE: 4

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/249,543DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW

145 <400> SEQUENCE: 13  
146 tcgagggctg cgtatccggt gacaccattg taatga 36  
147 <210> SEQ ID NO 14  
148 <211> LENGTH: 36  
149 <212> TYPE: DNA  
150 <213> ORGANISM: Artificial Sequence  
151 <220> FEATURE:  
152 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
153 Synthesized From Methanobacterium  
154 thermoautotrophicum.  
155 <400> SEQUENCE: 14  
156 ctagtcatta caatggtgtc accggatacg cagccc 36  
157 <210> SEQ ID NO 15  
158 <211> LENGTH: 54  
159 <212> TYPE: DNA  
160 <213> ORGANISM: Artificial Sequence  
161 <220> FEATURE:  
162 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
163 Synthesized From Methanobacterium  
164 thermoautotrophicum.  
165 <400> SEQUENCE: 15  
166 tcgagggcat cgaggcaacc aacggatccg tatccggtga caccattgta atga 54  
167 <210> SEQ ID NO 16  
168 <211> LENGTH: 54  
169 <212> TYPE: DNA  
170 <213> ORGANISM: Artificial Sequence  
171 <220> FEATURE:  
172 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
173 Synthesized From Methanobacterium  
174 thermoautotrophicum.  
175 <400> SEQUENCE: 16  
176 ctagtcatta caatggtgtc accggatacg gatccgttg ttgcctcgat gccc 54  
177 <210> SEQ ID NO 17  
178 <211> LENGTH: 54  
179 <212> TYPE: DNA  
180 <213> ORGANISM: Artificial Sequence  
181 <220> FEATURE:  
182 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
183 Synthesized From Methanobacterium  
184 thermoautotrophicum.  
185 <400> SEQUENCE: 17  
186 tcgagggcat cgaggcaacc aacggcgccg tatccggtga caccattgta atga 54  
187 <210> SEQ ID NO 18  
188 <211> LENGTH: 54  
189 <212> TYPE: DNA  
190 <213> ORGANISM: Artificial Sequence  
191 <220> FEATURE:  
192 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
193 Synthesized From Methanobacterium  
194 thermoautotrophicum.

PAGE: 5

RAW SEQUENCE LISTING  
PATENT APPLICATION US/09/249,543DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW

195 <400> SEQUENCE: 18  
 196 ctagtcatta caatggtgtc accggatacg gcgccgttgg ttgcctcgat gcc 54  
 197 <210> SEQ ID NO 19  
 198 <211> LENGTH: 28  
 199 <212> TYPE: DNA  
 200 <213> ORGANISM: Artificial Sequence  
 201 <220> FEATURE:  
 202 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
 203 Synthesized From Methanobacterium  
 204 thermoautotrophicum.  
 205 <400> SEQUENCE: 19  
 206 gtacacgcat gcggcgagca gcccgga 28  
 207 <210> SEQ ID NO 20  
 208 <211> LENGTH: 28  
 209 <212> TYPE: DNA  
 210 <213> ORGANISM: Artificial Sequence  
 211 <220> FEATURE:  
 212 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
 213 Synthesized From Methanobacterium  
 214 thermoautotrophicum.  
 215 <400> SEQUENCE: 20  
 216 ccggtcccgg gctgctcgcc gcatgcgt 28  
 217 <210> SEQ ID NO 21  
 218 <211> LENGTH: 14  
 219 <212> TYPE: PRT  
 220 <213> ORGANISM: Artificial Sequence  
 221 <220> FEATURE:  
 222 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
 223 Synthesized From Methanobacterium  
 224 thermoautotrophicum.  
 225 <400> SEQUENCE: 21  
 226 Thr Leu Glu Gly Cys Gly Glu Gln Pro Thr Gly (Xaa) Leu Lys  
 227 1 5 10  
 228 <210> SEQ ID NO 22  
 229 <211> LENGTH: 7  
 230 <212> TYPE: PRT  
 231 <213> ORGANISM: Artificial Sequence  
 232 <220> FEATURE:  
 233 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically  
 234 Synthesized From Methanobacterium  
 235 thermoautotrophicum.  
 236 <400> SEQUENCE: 22  
 237 Cys Gly Glu Gln Pro Thr Gly  
 238 1 5  
 239 <210> SEQ ID NO 23  
 240 <211> LENGTH: 462  
 241 <212> TYPE: DNA  
 242 <213> ORGANISM: Artificial Sequence  
 243 <220> FEATURE:  
 244 <223> OTHER INFORMATION: Description of Artificial Sequence: Chemically

W--&gt;

written on Enu  
summary  
sheet

PAGE: 6

VERIFICATION SUMMARY  
PATENT APPLICATION US/09/249,543

DATE: 02/26/1999  
TIME: 10:07:01

Input Set: I249543.RAW

Line ? Error/Warning


Original Text

-----  
226 W "N" or "Xaa" used: Feature required

-----  
Thr Leu Glu Gly Cys Gly Glu Gln Pro Thr G

# **RAW SEQUENCE LISTING** **ERROR REPORT**

BIOTECHNOLOGY  
SYSTEMS  
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number: 09/249,543  
Art Unit / Team No. : 01P2  
Date Processed by STIC: 2/26/99

**THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.**

**PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:**

**1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,**

**2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY**

**THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.**

**IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:**

**ARTI SHAH 703-308-4212**

Docket: NEB-154

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Evans, et al. EXAMINER: W. Moore  
SERIAL NO.: 09/249,543 GROUP: 1652  
FILED: February 12, 1999  
FOR: Intein-Mediated Protein Ligation of Expressed Proteins

The Honorable Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:


**STATEMENTS IN SUPPORT OF FILING AND SUBMISSIONS  
IN ACCORDANCE WITH 37 C.F.R. §§1.821.1-1.825**

In accordance with 37 C.F.R. §§1.821-1.825, I hereby state that the content of the paper and computer-readable copy of the sequence listing submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. I hereby state that the submission, filed in accordance with 37 C.F.R. §1.821(g) does not introduce new matter.

Respectfully submitted,

NEW ENGLAND BIOLABS, INC.

Date: 9/8/99

  
\_\_\_\_\_  
Gregory D. Williams  
(Reg. No.: 30901)  
Attorney for Applicant  
32 Tozer Road  
Beverly, MA 01915